Response to the letter to the Editor concerning manuscript entitled, 'Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide'

Subjects

Subjects :

Oncology
medicine.medical_specialty
Letter to the editor
Vomiting
medicine.medical_treatment
Antineoplastic Agents
Ondansetron
Chemotherapy induced
Glioma
Internal medicine
Temozolomide
medicine
Humans
Aprepitant
business.industry
Nausea
medicine.disease
Open label
business
Adjuvant
medicine.drug

Details

ISSN :

14337339 and 09414355

Volume :

28

Database :

OpenAIRE

Journal :

Supportive Care in Cancer

Accession number :

edsair.doi.dedup.....0d3e6e796c7b925eb002d83865ffe6f1

Full Text :

https://doi.org/10.1007/s00520-020-05726-0